Pérez‐Persona E, Cuevas Palomares L, Unamunzaga Cilaurren A, Gutiérrez López de Ocáriz X, Buendía Ureña B, Vega González de Viñaspre A, Benito Ibarrondo B, Molinillo Fernández MC, Cordero Osúa A, Benítez Delgado B, García Albás JJ, Andrés Moralejo MÁ, Guinea de Castro JM. Ultrafast 30-min infusion of a rituximab biosimilar (Truxima).
EJHaem 2023;
4:1196-1199. [PMID:
38024594 PMCID:
PMC10660389 DOI:
10.1002/jha2.812]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 09/27/2023] [Accepted: 10/02/2023] [Indexed: 12/01/2023]
Abstract
In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day-care hospital stays.
Collapse